Our Portfolio

Our companiesin action

Our diverse portfolio features disruptive biotech ventures with exceptional teams and innovative science.

Adcendo 

Denmark

Adcendo

Adcendo aps is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (adcs).

Region

Denmark

Fund

YBF lll

Latest news

AELIX Therapeutics 

Spain

AELIX Therapeutics

Aelix Therapeutics is a clinical-stage company developing a vaccine to treat HIV infection. The company is a spin-off of HIVACAT.

Region

Spain

Fund

YBF ll

Latest news

AM Pharma 

The Netherlands

AM Pharma

AM-Pharma B.V. is a biopharmaceutical company focused on preclinical and clinical development of alkaline phosphatase (AP) as a treatment for severe inflammatory diseases.

Region

The Netherlands

Fund

YBF l & YBF ll

Latest news

Anaconda Biomed 

Spain

Anaconda Biomed

Anaconda BioMed, headquartered in Barcelona, Spain, is among the world’s most innovative early stage medical technology companies.

Region

Spain

Fund

YBF ll

Latest news

Aura Biosciences 

(NASDAQ: AURA)

USA

Aura Biosciences

Aura Biosciences is applying nanotechnology to the fight against cancer. Its novel viral nanoparticle technology, developed in partnership with the National Cancer Institute (NCI), harnesses the potential of viral evolution and tumor targeting for the treatment of cancer.

Region

USA

NASDAQ

AURA

Fund

YBF ll

Latest news

Babyscripts 

USA

Babyscripts

Babyscripts is a clinically validated, digital healthcare company focused on using internet-enabled medical devices and mobile apps to detect problems in pregnancy faster and rethink the delivery of pregnancy care.

Region

USA

Fund

YBF ll

Latest news

BioVex 

(Acq. Amgen)

USA

BioVex

BioVex was a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease using oncolytic viruses.

Region

USA

Acquired by

Amgen

Fund

YBF l

Latest news

CorWave 

France

CorWave

CorWave is a French medtech company developing next-generation blood pumps for heart failure patients.

Region

France

Fund

YBF ll

Latest news

CVRx 

(NASDAQ: CVRX)

USA

CVRx

CVRx® developed a proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim neo uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. Barostim neo can be adjusted to meet each patient’s individual therapy needs.

Region

USA

NASDAQ

CVRX

Fund

YBF l

Latest news

Cytoki Pharma 

Denmark

Cytoki Pharma

CytoKi Pharma is a biotechnology company engaged in the development of protein drugs for diseases characterized by epithelial injury, with focus on developing a licensed long-acting IL-22 program for Inflammatory Bowel Disease and potentially additional clinical indications.

Region

Denmark

Fund

YBF lll

Latest news

EndoSense 

(Acq. St Jude Medical/Abbott)

Switzerland

EndoSense

Endosense was a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias.

Region

Switzerland

Acquired by

St Jude Medical/Abbott

Fund

YBF l

Latest news

Galecto Biotech 

(NASDAQ: GLTO)

Denmark

Galecto Biotech

Galecto is focused on developing novel drugs for the treatment of fibrosis, inflammation, and cancer based on targeting galectins, a group of proteins shown to be involved in many disease processes. Galecto’s team of scientists and experts has shown in preclinical and clinical studies that the company’s high potency galectin modulators may open new treatment possibilities for many patients. The company’s lead product, TD139, is an inhaled galectin-3 inhibitor in Phase II/III studies for the treatment of idiopathic pulmonary fibrosis (IPF). Galecto is located in Copenhagen, Denmark.

Region

Denmark

NASDAQ

GLTO

Fund

YBF ll

Latest news

Inbiomotion 

Spain

Inbiomotion

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Region

Spain

Fund

YBF l

Latest news

Kala Pharmaceuticals 

(NASDAQ: KALA)

USA

Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary mucus-penetrating particle technology, with a focus on the treatment of eye diseases. Kala’s first product, INVELTYS® for the treatment of inflammation and pain following ocular surgery, was approved in 2019 and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease is in phase III trials

Region

USA

NASDAQ

KALA

Fund

YBF l

Latest news

LAVA Therapeutics 

(NASDAQ: LVTX)

The Netherlands

LAVA Therapeutics

LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers.

Region

The Netherlands

NASDAQ

LVTX

Fund

YBF lll

Latest news

MedLumics 

Spain

Minoryx Therapeutics 

Spain

Minoryx Therapeutics

Minoryx is a clinical-stage biotech company developing new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program leriglitazone (MIN-102) has completed a Phase II/III clinical trial for the treatment of adrenomyeloneuropathy, the most common phenotype of X-linked Adrenoleukodystrophy, and a Phase II study in Friedreich’s Ataxia.

Region

Spain

Fund

YBF ll

Latest news

Ona Therapeutics 

Spain

Ona Therapeutics

Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism

Region

Spain

Fund

YBF lll

Latest news

OxThera 

Sweden

OxThera

OxThera is a biopharmaceutical company with products in late-stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for dietary hyperoxaluria and prevention of kidney stones.

Region

Sweden

Fund

YBF ll

Latest news

Prexton Therapeutics 

(Acq. Lundbeck)

Switzerland

Prexton Therapeutics

Prexton Therapeutics had the mission to develop innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders.

Region

Switzerland

Acquired by

Lundbeck

Fund

YBF ll

Latest news

Sanifit 

(Acq. Vifor Pharma)

Spain

Sanifit

Sanifit is a clinical-stage biopharmaceutical company focused on the development of SNF472, an experimental drug for the treatment of cardiovascular diseases linked to calcification in the end-stage renal disease population undergoing haemodialysis.

Region

Spain

Acquired by

Vifor Pharma

Fund

YBF ll

Latest news

SparingVision 

France

SparingVision

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases.

Region

France

Fund

YBF lll

Latest news

SpliceBio 

Spain

SpliceBio

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases.

Region

Spain

Fund

YBF lll

Latest news

STAT Dx 

(Acq. Qiagen)

Spain

STAT Dx

STAT-DX was developin near-patient testing products for healthcare professionals with short turnaround time applications and critical care.

Region

Spain

Acquired by

Qiagen

Fund

YBF l

Latest news

Synendos 

Switzerland

Synendos

Synendos Therapeutics is a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS)

Region

Switzerland

Fund

YBF lll

Latest news

TiGenix 

(Acq. Takeda Pharmaceuticals)

Spain

TiGenix

Initial investment in Cellerix, founded in 2004. Cellerix was a biopharmaceutical company developing innovative treatments based on a cell therapy. Subsequently it reverse-merged with Tigenix listed on Euronext. Tigenx was Acquired in July 2018 by Takeda Pharmaceuticals.

Region

Spain

Acquired by

Takeda Pharmaceuticals

Fund

YBF l

Latest news

VarmX 

The Netherlands

VarmX

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, founded in 2016, that is specialized in the discovery and development of therapeutic proteins for the prevention and treatment of bleeding. The company’s leading product in development, VMX-C001, is a new therapeutic protein to prevent or stop severe bleeding in patients taking blood thinners in the form of direct factor Xa inhibitors.

Region

The Netherlands

Fund

YBF lll

Latest news

Vivet Therapeutics 

France/Spain

Vivet Therapeutics

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases including Wilson Disease, Progressive Familiar Intrahepatic Cholestasis (PFIC) and other indications. Vivet is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression.

Region

France/Spain

Fund

YBF ll

Latest news

Xeltis 

Switzerland/The Netherlands

Xeltis

Xeltis is a clinical-stage medical device company pioneering a restorative approach in heart valve and vascular therapy. Xeltis technology platform is based on Endogenous Tissue Restoration.

Region

Switzerland/The Netherlands

Fund

YBF ll

Latest news